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Affective disorders like depression rank worldwide among
the most disabling in terms of WHO global burden of
disease, are socioeconomically relevant, severe and pre-
valent. Due to persisting cognitive symptoms, these dis-
eases lead to enormous social disabilities and they
dramatically increase the risk of suicide. A genetic influ-
ence and the serotonin transporter (5HTT) play a major
role in the pathophysiology of mood disorders and suicidal
behavior. Pinto et al. [1] investigated the effect of genomic
imprinting of the four 5HTT genetic markers and expres-
sion of 5HTT alleles in lymphocytes of suicide attempters
and 312 nuclear families with at least one member affected
by bipolar disorder. Allele 2651T was transmitted more
often to bipolar patients, but the authors did not find dif-
ferential gene expression between bipolar suicide attemp-
ters and non-attempters, which does not support a role for
allelic expression of 5HTT in suicidal behavior.
Due to the high risk of suicide and social disabilities
despite antidepressant medication, add-on therapy entailing
fewer side effects should be investigated. Tajalizadekhoob
et al. [2] applied fish oil capsules containing polyunsatu-
rated fatty acids (PUFAs) in elderly patients with mild to
moderate depression as add-on therapy during a period of
six months. Treatment with PUFAs showed significant
effects compared to placebo and may be beneficial in
depressed elderly patients who are at greater risk for car-
diovascular diseases. In fact, major depression is associated
with increased volumes of visceral fat and high prevalence
of the metabolic syndrome, leading to coronary artery
disease. Greggersen et al. [3] investigated visceral fat
content in young depressed women with and without
comorbid borderline personality disorder. They found a
significant increase in visceral fat content in major
depression, but no additional effects of borderline person-
ality disorder, which does not seem to be an additive risk
factor for the metabolic syndrome.
Sleep disturbances are common in both depressed and
alcohol-dependent patients, including decreased slow wave
sleeps (SWS). Brower et al. [4] compared power spectral
analysis of polysomnography recordings in men with
alcohol dependence compared to subjects with major
depression. Both groups showed blunted slow wave
activities: men with major depression showed the least
slow wave activities in the first non-REM period, whereas
men with alcohol dependence had the slowest slow wave
activity decay rate. New treatment approaches should
selectively improve these different components of sleep
homeostasis. In a study by Cordes et al. [5], antidepressant
therapy with clomipramine has shown to induce a signifi-
cant increase in serum prolactin levels in women, but not in
men with major depression, indicating effects of clomip-
ramine on the central monoaminergic system. In line with a
glutamate hypothesis of depression, the N-methyl-D-
aspartate (NMDA) receptor antagonist ketamine has been
shown to be therapeutically effective in unipolar and
bipolar depression. In a retrospective chart analysis of
Kranaster et al. [6], effects of ketamine as anesthetic during
electroconvulsive therapy (ECT) in patients with therapy-
resistant depression have been compared to anesthesia with
the barbiturate thiopental. Interestingly, the ketamine group
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needed fewer ECT sessions and had lower HAMD and higher
MMSE scores after treatment, pointing toward synergistic
effects of ECT and ketamine as well as fewer cognitive side
effects. The tolerability was good aside from more comedi-
cation for blood pressure control in the ketamine group.
Kebir and Joober [7] reviewed results from genetic
studies investigating associations between susceptibility
genes for attention-deficit hyperactivity disorder (ADHD)
and neuropsychological traits relevant for the disorder. The
most consistent result was the association between the
DRD4 gene and high reaction time variability, whereas
many findings of association with other genes need repli-
cation. Furthermore, Fasmer et al. report a higher preva-
lence of migraine in ADHD [8], pointing to a comorbidity
between ADHD and migraine.
In order to improve compliance and enhance therapeutic
alliance, patients should at least trust in their treating
psychiatrists. Minamisawa et al. [9] investigated this issue
in 504 outpatients of a psychiatric clinic using a self-report
questionnaire. The trust in psychiatrists was higher with
longer treatment duration and a longer than 10 years
expertise of psychiatrists, but also dependent on diagnosis,
since F4 patients showed lesser trust in their psychiatrists
than F3 patients. Altogether, we should continue to develop
better treatment strategies for psychiatric diseases, entail-
ing fewer side effects to achieve better response to treat-
ment and to improve the patient’s trust in our efforts.
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